Evidence map›Paper›PMID 38399949›Full record

SynthesisViruses2024

Antiviral Defence Mechanisms during Early Mammalian Development.

Felix Mueller, Jeroen Witteveldt, Sara Macias

Abstract readMeta-AnalysisReview
In one paragraph

Synthesis in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Felix MuellerInstitute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, King's Buildings, Charlotte Auerbach Road, Edinburgh EH9 3FL, UK.
Jeroen WitteveldtInstitute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, King's Buildings, Charlotte Auerbach Road, Edinburgh EH9 3FL, UK.
Sara MaciasInstitute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, King's Buildings, Charlotte Auerbach Road, Edinburgh EH9 3FL, UK.ORCID 0000-0002-0643-3494

Funding

Wellcome TrustWellcome Trust 221737/Z/20/Z
6 · The paper itself

Abstract

The type-I interferon (IFN) response constitutes the major innate immune pathway against viruses in mammals. Despite its critical importance for antiviral defence, this pathway is inactive during early embryonic development. There seems to be an incompatibility between the IFN response and pluripotency, the ability of embryonic cells to develop into any cell type of an adult organism. Instead, pluripotent cells employ alternative ways to defend against viruses that are typically associated with safeguard mechanisms against transposable elements. The absence of an inducible IFN response in pluripotent cells and the constitutive activation of the alternative antiviral pathways have led to the hypothesis that embryonic cells are highly resistant to viruses. However, some findings challenge this interpretation. We have performed a meta-analysis that suggests that the susceptibility of pluripotent cells to viruses is directly correlated with the presence of receptors or co-receptors for viral adhesion and entry. These results challenge the current view of pluripotent cells as intrinsically resistant to infections and raise the fundamental question of why these cells have sacrificed the major antiviral defence pathway if this renders them susceptible to viruses.

Indexed as

Interferon Type IVirusesAnimalsAntiviral AgentsImmunity, InnateMammalsAntiviral AgentsInterferon Type IantiviralblastocystdevelopmentdsRNAembryonic stem cellsinnate immunityinterferontransposable elementtransposonvirus

Identifiers

PMID38399949
PMCPMC10891733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.